Artificial intelligence and machine learning (AI/ML) are quickly becoming the norm in biopharma, with now the vast majority of drug companies implementing the technology in some way or another. Most of that has been in drug discovery and development, but it is also moving into manufacturing, marketing and regulatory functions. But as use expands, there are associated risks that companies will have to mitigate, including in areas such as data privacy, cybersecurity and intellectual property.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?